Tango Therapeutics appoints Robert Azelby to board; receives option for 35,910 shares at $27.97

Tango Therapeutics, Inc.

Board expanded to seven directors; Azelby fills newly created vacancy as Class II director term expiring 2029.
Azelby is independent; will serve on Compensation and Nominating/Corporate Governance committees.
Receives equity: option to purchase 35,910 shares at $27.97, plus RSU for 5,740 shares, vesting over 3 years.
Annual retainer of $45,000 for board service plus committee retainers of $7,500 and $5,000.
Azelby brings 30+ years biopharma experience including Juno and Amgen; company advancing vopimetostat for pancreatic cancer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Azelby

Director

TNGX · Tango Therapeutics, Inc.

Effective: 2026-06-19
Filed: June 23, 2026, 5:19 PM ET

the Board appointed Robert Azelby as a director of the Company to fill the newly created vacancy on the Board resulting from the increase to the board size.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Robert Azelby was appointed as Director at Tango Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Robert Azelby as a director of the Company to fill the newly created vacancy on the Board resulting from the increase to the board size.

View on SEC.gov

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-279788

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.